睡茄治疗焦虑症和失眠症的安全性和有效性：系统回顾和荟萃分析。

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY Human Psychopharmacology: Clinical and Experimental Pub Date : 2024-07-31 DOI:10.1002/hup.2911

Kaneez Fatima, Javeria Malik, Fariha Muskan, Ghana Raza, Areesha Waseem, Hiba Shahid, Syeda Fatima Jaffery, Umeed Khan, Muhammad Kashan Zaheer, Yasmeen Shaikh, Ahmed Mustafa Rashid

{"title":"睡茄治疗焦虑症和失眠症的安全性和有效性：系统回顾和荟萃分析。","authors":"Kaneez Fatima, Javeria Malik, Fariha Muskan, Ghana Raza, Areesha Waseem, Hiba Shahid, Syeda Fatima Jaffery, Umeed Khan, Muhammad Kashan Zaheer, Yasmeen Shaikh, Ahmed Mustafa Rashid","doi":"10.1002/hup.2911","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Despite the historical neurological use of <i>Withania somnifera,</i> limited evidence supports its efficacy for conditions like anxiety and insomnia. Given its known anti-stress properties, this review evaluated its safety and efficacy for anxiety and insomnia.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We searched Medline, Cochrane Library, and Google Scholar until August 2023 for randomized controlled trials (RCTs) comparing <i>W. somnifera</i> to placebo in patients with anxiety and/or insomnia. Outcome measures included changes in anxiety levels via the Hamilton Anxiety Scale (HAM-A), Sleep Onset Latency (SOL), Total Sleep Time (TST), Wake After Sleep Onset (WASO), Total Time in Bed (TIB), Sleep Efficiency (SE), and Pittsburgh Sleep Quality Index (PSQI) score. We utilized a random-effect model for pooling Mean Differences (MD) with a 95% Confidence Interval (CI). Heterogeneity was assessed through sensitivity and subgroup analysis, and the quality of RCTs was evaluated using the Cochrane revised risk of bias tool.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Pooled results from five RCTs (<i>n</i> = 254) demonstrated that <i>W. somnifera</i> significantly reduced HAM-A scores (MD = −5.96; [95% CI −10.34, −1.59]; <i>P</i> = 0.008; <i>I</i><sup>2</sup> = 98%), as well as sleep parameters such as SOL, TST, PSQI, and SE, but not WASO and TIB.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>While <i>W. somnifera</i> extracts yielded promising results, further research with larger sample sizes is needed to confirm its effects on anxiety and insomnia.</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"39 6","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta-analysis\",\"authors\":\"Kaneez Fatima, Javeria Malik, Fariha Muskan, Ghana Raza, Areesha Waseem, Hiba Shahid, Syeda Fatima Jaffery, Umeed Khan, Muhammad Kashan Zaheer, Yasmeen Shaikh, Ahmed Mustafa Rashid\",\"doi\":\"10.1002/hup.2911\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>Despite the historical neurological use of <i>Withania somnifera,</i> limited evidence supports its efficacy for conditions like anxiety and insomnia. Given its known anti-stress properties, this review evaluated its safety and efficacy for anxiety and insomnia.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We searched Medline, Cochrane Library, and Google Scholar until August 2023 for randomized controlled trials (RCTs) comparing <i>W. somnifera</i> to placebo in patients with anxiety and/or insomnia. Outcome measures included changes in anxiety levels via the Hamilton Anxiety Scale (HAM-A), Sleep Onset Latency (SOL), Total Sleep Time (TST), Wake After Sleep Onset (WASO), Total Time in Bed (TIB), Sleep Efficiency (SE), and Pittsburgh Sleep Quality Index (PSQI) score. We utilized a random-effect model for pooling Mean Differences (MD) with a 95% Confidence Interval (CI). Heterogeneity was assessed through sensitivity and subgroup analysis, and the quality of RCTs was evaluated using the Cochrane revised risk of bias tool.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Pooled results from five RCTs (<i>n</i> = 254) demonstrated that <i>W. somnifera</i> significantly reduced HAM-A scores (MD = −5.96; [95% CI −10.34, −1.59]; <i>P</i> = 0.008; <i>I</i><sup>2</sup> = 98%), as well as sleep parameters such as SOL, TST, PSQI, and SE, but not WASO and TIB.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>While <i>W. somnifera</i> extracts yielded promising results, further research with larger sample sizes is needed to confirm its effects on anxiety and insomnia.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13030,\"journal\":{\"name\":\"Human Psychopharmacology: Clinical and Experimental\",\"volume\":\"39 6\",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Psychopharmacology: Clinical and Experimental\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hup.2911\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2911","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：尽管历史上曾在神经系统中使用过睡莲属植物，但支持其治疗焦虑和失眠等病症疗效的证据有限。鉴于其已知的抗应激特性，本综述对其治疗焦虑和失眠的安全性和有效性进行了评估：我们检索了 Medline、Cochrane 图书馆和谷歌学术（Google Scholar）中截至 2023 年 8 月的随机对照试验（RCT），这些试验对焦虑和/或失眠患者进行了 somnifera 与安慰剂的比较。结果测量包括通过汉密尔顿焦虑量表（HAM-A）得出的焦虑水平变化、睡眠开始延迟（SOL）、总睡眠时间（TST）、睡眠开始后觉醒（WASO）、卧床总时间（TIB）、睡眠效率（SE）和匹兹堡睡眠质量指数（PSQI）得分。我们采用随机效应模型对平均差 (MD) 和 95% 置信区间 (CI) 进行了汇总。通过敏感性和亚组分析评估了异质性，并使用科克伦修订的偏倚风险工具评估了研究性研究的质量：来自五项研究性试验（n = 254）的汇总结果表明，桑尼佛陀能显著降低 HAM-A 评分（MD = -5.96；[95% CI -10.34，-1.59]；P = 0.008；I2 = 98%）以及 SOL、TST、PSQI 和 SE 等睡眠参数，但不能降低 WASO 和 TIB：虽然索姆尼佛拉萃取物产生了令人鼓舞的结果，但还需要进行样本量更大的进一步研究，以确认其对焦虑和失眠的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta-analysis

Objective

Despite the historical neurological use of Withania somnifera, limited evidence supports its efficacy for conditions like anxiety and insomnia. Given its known anti-stress properties, this review evaluated its safety and efficacy for anxiety and insomnia.

Methods

We searched Medline, Cochrane Library, and Google Scholar until August 2023 for randomized controlled trials (RCTs) comparing W. somnifera to placebo in patients with anxiety and/or insomnia. Outcome measures included changes in anxiety levels via the Hamilton Anxiety Scale (HAM-A), Sleep Onset Latency (SOL), Total Sleep Time (TST), Wake After Sleep Onset (WASO), Total Time in Bed (TIB), Sleep Efficiency (SE), and Pittsburgh Sleep Quality Index (PSQI) score. We utilized a random-effect model for pooling Mean Differences (MD) with a 95% Confidence Interval (CI). Heterogeneity was assessed through sensitivity and subgroup analysis, and the quality of RCTs was evaluated using the Cochrane revised risk of bias tool.

Results

Pooled results from five RCTs (n = 254) demonstrated that W. somnifera significantly reduced HAM-A scores (MD = −5.96; [95% CI −10.34, −1.59]; P = 0.008; I² = 98%), as well as sleep parameters such as SOL, TST, PSQI, and SE, but not WASO and TIB.

Conclusion

While W. somnifera extracts yielded promising results, further research with larger sample sizes is needed to confirm its effects on anxiety and insomnia.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Human Psychopharmacology: Clinical and Experimental 医学-精神病学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design